28Mar 2018

A CRITIQUE ON CANCER VACCINE.

  • Department of Pharmaceutics.
  • Department of Pharmacy Practice.
  • Department of Pharmacology J.K.K. Nattraja College of Pharmacy, Kumarapalayam, Tamilnadu - 638183, India.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

The goal of a successful vaccine is to prepare the immune system for invasion of a foreign pathogen and teach them to recognize antigens as well as reduce the risk of transmission. In the field of cancer, vaccines are found to be the latest discovery. Provenge? (Sipuleucel-T) is the only vaccine approved by Food and Drug Administration for the treatment of cancer. Vaccines are an appealing therapeutic strategy because they are specific. In addition they stimulate the adaptive immune system, thereby producing a memory response allowing for sustained effect without repeated therapy. Revelation of a potential anticancer treatment is as yet a test to the researchers. Thus, the development of effective cancer vaccines require, thoughtful clinical trials, and scientific progress which might induce long-term specific anticancer response and could contribute to effective and lasting elimination of malignant cells.

  1. IARC, World cancer report, (WHO). 2003.
  2. Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer. 2004;4(11):909-917.
  3. Jaganti V, Sukirti DT, Sai S. A review on cancer vaccines.Int J Pharma Bio Sci. 2011;2(3):86-97.
  4. Cancer ? The role of genes, lifestyle & environment by Joseph Panno, PhD.
  5. Claudia N. Bibliotheca Alexandrina 120433. Available from:
http://www.bibalex.org/libraries/presentation/static/Cancer_Vaccines _eng_ 1204.pdf.
  1. Itoh K. Jpn J Clin Oncol. 2009;39:73-80.
  2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Impact study investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
  3. Madan RA, Gulley JI, Fojo T, Dahut WI. Therapeutic cancer vaccines in prostate cancer: The paradox of improved survival without changes in time to progression. 2010;15(9):969-975.
  4. Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J et al. A phase III multi institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patient with metastatic melanoma. J Clin Oncol. 2009;27:18.
  5. Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol. 2009;27(suppl; abstr2):
  6. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M et al. Overall survival analysis of a phase II randomized controlled trial of a pox-viral based PSA-targeted immunotherapy metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-1105.
  7. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 2002;53(2):109-17.
  8. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J et al. Recombinant vaccinia-PSA(PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999;53(2):260-266.
  9. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J et al. 2000. A phase I trial of a recombinant vaccinia virus expressing prostate specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6(5):1632-1638.
  10. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW et al. Clinical safety of a viral vector based prostate cancer vaccinestrategy. J Urol. 2007;178(4 pt 1):1515-1520.
  11. Dipaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1,ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006;4:1.
  12. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18(7):1001-1011.
  13. Gulley JL, Madan RA, Tsang KY, Jochems C, Mart JL, Farsaci B et al. Immune impact induced by PROSTVAC (PSA-TRICOM), therapeutic vaccine for prostate cancer. Cancer Immunol Res. 2014;2(2):133-141.
  14. Gardasil? prescribing information (gardasil.com.)
  15. Merck & Co, Inc. form 10-K as filed with the securities and exchange commission on march 1; 2010.
  16. GlaxoSmithKline plc form 20-F as filed with the securities and exchange commission on march 1; 2010.
  17. Karsten U, Mensdorff-Pouilly SV, Goletz S. What makes MUC1 a tumor antigen. Tumor Biol. 2005;26:217-220.
  18. Duraisamy S, Kufe T, Ramasamy S, Kufe D. Evolution of the human MUC1 oncoprotein. Int J Oncol. 2007;31(3):671-677.
  19. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57(2):327-334.
  20. Marshall J. Carcinoembryonic antigen-based vaccines. Semin Oncol. 2003;30(3 supp 8):30-36.
  21. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant non replicating avian pox virus to elicit anticarcinoembryonic antigen immune responses. J Clin Oncol. 2000;18(23):3964-3973.
  22. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian pox viruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immune adjuvant. Cancer Res. 2001;61(1):206-214.
  23. Morse MA, Clay TM, Hobeika AC. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005;11(8):3017-3024.
  24. Morse MA, Nair SK, Mosca PJ. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 2003;21(3):341-349.
  25. Brossart P, Wirths S, Stuhler G. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96(9):3102-3108.
  26. Wobser M, Keikavoussi P, Kunzmann V. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother. 2006;55(10):1294-1298.
  27. Otto K, Andersen MH, Eggert A. Lack of toxicity of therapy-induced T cell responses against the universal tumor antigen survivin. Vaccine. 2005;23(7):884-889.
  28. Taylor-Papadimitriou J, Finn OJ. Biology, biochemistry and immunology of carcinoma associated mucins. Immunol Today. 1997;18:105-107.
  29. Vonderheide RH, Hahn WC, Schultze JL. The telomerase catalytic subunit is a widelyexpressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10(6):673-679.
  30. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumor prevention. Nat Rev Cancer. 2006;6(3):204-216.
  31. Michael L. Beating cancer with natural medicine. Library of congress control. 2003;56.
  32. Matthias R. Cellular health series: cancer, first edition, MR publishing, inc. 2001;50-52.
  33. Kumar P, Prasanthi S, Lakshmi VRS, Saisantosh MV. Cancer vaccines: A promising role in cancer therapy. AJCR. 2010;3:16-21.
  34. Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treat Res. 2005;123:89-111.
  35. Bendle GM, Holler A, Downs AM, Xue SA, Stauss HJ. Broadly expressed tumor associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. Expert Opin Biol Ther. 2005;5(9):1183-1192.
  36. Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin immunol. 2008;20(5):276-285.
  37. Treatment immunotherapy: tumor cell vaccines. Melanoma centre. Available from:http://www.melanomacenter.org/treatment/tumhtml.
  38. Cheuk AT, Guinn BA. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine. Front Biosci. 2008;13:2022-2029.
  39. Stevenson GT, Stevenson FK. Antibody to a molecularly-defined antigen confined to a tumor cell surface. 1975;254:714-716.
  40. Timmerman JM, Czerwinski DK, Davis TA. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. 2002;99(5):1517-1526.
  41. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. 1998;161(12):6532-6536.
  42. Chan K, Lee DJ, Schubert A, Tanq CM, Crain B, Schoenberger SP et al. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA. J Immunol. 2001;166(5):3061-3066.
  43. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol. 2012;12(6):648-657.
  44. Victoria AP, Rachael LM, Barbara G, Ian S, Judith MR, Lindy GD. DNA vaccination with T-cell epitopes encoded within molecules induces high-avidity anti-tumor CD81 T cells. EurJ Immunol. 2010;40(3):899-910.
  45. Schalk JA, Mooi FR, Berbers GA, Vanaerts LA, Ovelgonne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccine. 2006;2(2):45-53.
  46. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Aca Sci USA. 1982;79(23):7415-7419.
  47. Drexler I, Staib C, Sutter G. Modified vaccinia virus ankara as antigen delivery system: how can we best use its potential. Curr Opin Biotechnol. 2004;15(6):506-512.
  48. Souza AP, Haut L, Reyes-Sandoval A, Pinto AR. Recombinant viruses as vaccines against viral diseases. Braz J Med Biol Res. 2005;38(4):509-522.
  49. Debruyn G, Rossini AJ, Chiu YL. Safety profile of recombinant canary pox HIV vaccines. Vaccine. 2004;22(5-6):704-713.
  50. Ludwig. Update 2-Merck to test stimuvax cancer drug in Phase III. 2009.
  51. Luigi B, Annacarmen P, Maria LT, Franco MB. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol. 2011;18(1):23-34.
  52. Bruce G, Laura D. The cancer vaccine roller coaster. Nat Biotechnol. 2009;27(2):129-139.
  53. Kuyler D, Shelly B, Philip V. The ongoing hopes and challenges of cancer oncology business review. 2010.

[Sambathkumar R, Amala Baby, Sudha M and Venkateswaramurthy N. (2018); A CRITIQUE ON CANCER VACCINE. Int. J. of Adv. Res. 6 (Mar). 1363-1370] (ISSN 2320-5407). www.journalijar.com

Sambathkumar R,
J.K.K Nattraja College of Pharmacy

DOI:

Article DOI: 10.21474/IJAR01/6806      
DOI URL: https://dx.doi.org/10.21474/IJAR01/6806

Download Full Paper

Download PDF No. of Downloads: 11 | No. of Views: 66